Browsing publications by Professor Nicola Curtin

Newcastle AuthorsTitleYearFull text
Maryam Zanjirband Zanjirband
Professor Nicola Curtin
Professor John Lunec
Combination treatment with rucaparib (Rubraca) and MDM2 inhibitors, Nutlin-3 and RG7388, has synergistic and dose reduction potential in ovarian cancer2017
Professor Nicola Curtin
Opportunities for the repurposing of PARP inhibitors for the therapy of non-oncological diseases2017
Carlo Bawn
Martin Galler
Huw Thomas
Suzanne Kyle
Professor Nicola Curtin
et al.
PARP inhibitor rucaparib induces changes in NAD levels in cells and liver tissues as assessed by MRS2017
Dr Ashleigh Herriott
Dr Miranda Morton
Professor Nicola Curtin
Phase I, dose-escalation, two-part trial of the PARP inhibitor talazoparib in patients with advanced germline BRCA1/2 mutations and selected sporadic cancers2017
Professor Nicola Curtin
Strategies Employed for the Development of PARP Inhibitors2017
Dr Stuart Rundle
Alice Bradbury
Dr Yvette Drew
Professor Nicola Curtin
Targeting the ATR-CHK1 Axis in Cancer Therapy2017
Professor Nicola Curtin
The use of PARP inhibitors in cancer therapy: Use as adjuvant with chemotherapy or radiotherapy, use as a single agent in susceptible patients, and techniques used to identify susceptible patients2017
Dr Rachel O'Donnell
Dr Angelika Kaufmann
Dr Laura Woodhouse
Dr Aiste McCormick
Professor Richard Edmondson
et al.
Advanced Ovarian Cancer Displays Functional Intratumor Heterogeneity That Correlates to Ex Vivo Drug Sensitivity2016
Dr Peter Stephens
Professor Nicola Curtin
Chk1 phosphorylated at serine345 is a predictor of early local recurrence and radio-resistance in breast cancer2016
Barry Dent
Laura Ogle
Dr Rachel O'Donnell
Dr Ujjal Mallick
Professor Nicola Curtin
et al.
High-resolution imaging for the detection and characterisation of circulating tumour cells from patients with oesophageal, hepatocellular, thyroid and ovarian cancers2016
1234567891011121314151617181920...